Nichi-Iko Pharmaceutical Co., Ltd

Nichi-Iko Pharmaceutical Co. in its US$ 100 million sale to Ellimist Singapore Pte. Ltd.

Client

Nichi-Iko Pharmaceutical Co., Ltd

Value

$100 million

Service

Mergers and Acquisitions

Date Closed

February 2023

Industry

Pharmaceuticals and Life Sciences

Lead Office

Montréal

 

On February 28, 2023, Nichi-Iko Pharmaceutical Co., Ltd. sold all issued and outstanding shares of its wholly owned subsidiaries, Sagent Pharmaceuticals, based in Wyoming, and Omega Laboratories Ltd., based in Montreal, to Ellimist Singapore Pte. Ltd. for an aggregate purchase price of US$100 million.

Nichi-Iko Pharmaceutical Co.,Ltd. is a Japanese company that focuses on manufacturing and selling pharmaceutical and medical products.

Osler, Hoskin & Harcourt LLP advised Nichi-Iko Pharmaceutical Co. with a team led by Vincent de Grandpré (IP) and Hugo-Pierre Gagnon (Corporate) and consisting of Josh Blatt (Corporate), Alain Fournier and Jean-Philippe Dionne (Tax), Julien Ranger-Musiol and Jeremy Perron (Pension, Benefits & Employment), Shuli Rodal (Competition), Susan Newell (Health), Jennifer Fairfax (Environmental), Yan Besner and Natasha Vincelli (Real Estate), Alan Kenigsberg and Malcolm Aboud (Sanctions and Anti-Corruption) and Joanna Fine, Adam LaRoche and Gemma Devir (Privacy).